CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

Mutation

CIViC ID: 186 · Gene: BRCA2

Variant Summary

HGVS
Variant Type(s)
gene_variant,loss_of_function_variant
Evidence Items
21

Evidence Level Distribution

Level A: 4Level B: 16Level C: 1

Evidence Items

Showing CIViC evidence rows where gene = BRCA2 and variant = Mutation.

LevelTypeDirectionSignificanceDiseaseDrugsRating
APredictiveSupportsSensitivity/ResponseOvarian CancerRucaparib5
APredictiveSupportsSensitivity/ResponseOvarian CancerRucaparib5
APredictiveSupportsSensitivity/ResponseOvarian CancerOlaparib5
APredictiveSupportsSensitivity/ResponseCastration-resistant Prostate CarcinomaOlaparib5
BPredictiveSupportsSensitivity/ResponseCancerOlaparib4
BPredictiveSupportsSensitivity/ResponseBreast CancerOlaparib4
BPredictiveSupportsSensitivity/ResponsePancreatic CancerOlaparib4
BPredictiveSupportsSensitivity/ResponsePancreatic CancerPlatinum Compound4
BPredictiveSupportsSensitivity/ResponseOvarian CarcinomaPlatinum Compound3
BPredictiveSupportsSensitivity/ResponseOvarian CarcinomaPlatinum Compound3
BPrognosticSupportsBetter OutcomeOvarian Cancer3
BPredictiveSupportsSensitivity/ResponseOvarian CancerOlaparib,Cediranib3
BPredictiveSupportsSensitivity/ResponseTriple-receptor Negative Breast CancerCisplatin,Carboplatin3
BPredictiveSupportsSensitivity/ResponseOvarian CancerOlaparib3
BPredictiveDoes Not SupportSensitivity/ResponseTriple-receptor Negative Breast CancerOlaparib3
BPrognosticSupportsBetter OutcomeEpithelial Ovarian Cancer3
BPredictiveSupportsSensitivity/ResponsePancreatic CancerCisplatin,Veliparib,Gemcitabine3
BPredictiveDoes Not SupportSensitivity/ResponsePancreatic CancerVeliparib3
CPredictiveSupportsSensitivity/ResponsePancreatic CancerIniparib3
BPredictiveSupportsSensitivity/ResponseOvarian CancerRucaparib3
BPredictiveSupportsSensitivity/ResponseOvarian CancerRucaparib2